Le Lézard
Classified in: Health
Subject: SVY

Survey: More than Half of Male Patients with Lupus Report Feeling Depressed, Receiving Little Support


ATLANTA, Nov. 11, 2019 /PRNewswire/ -- A national survey of male patients with lupus finds the illness has a significant impact on their physical and emotional health, yet they often do not receive support that could help them cope. Researchers at Hospital for Special Surgery (HSS) in New York City launched a nationwide survey to assess the needs of male patients and found that 58% reported feeling depressed for several days or more than half the days in the previous two weeks. Regarding support and coping, 52% reported that they received no support. More than 80% of respondents indicated that lupus limited their activities of daily living, mostly due to pain and fatigue. 

HSS Logo (PRNewsfoto/Hospital for Special Surgery)

The findings were reported at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting on November 11 in Atlanta.

"It is a misconception that lupus affects only women. Although most of those affected are female, studies show males represent an estimated 4 to 22% of patients," explains Priscilla Toral, LCSW, program manager of Lupus Line®/Charla de Lupus (Lupus Chat)®, in the Department of Social Work Programs at HSS, which offers numerous support and education programs for people with lupus and their families. "Research has shown that the clinical presentation of lupus in men is very similar to what women experience. However, men often have more severe disease and tend to seek medical attention and supportive care less often than females."

Limited research exists regarding the specific medical, psychosocial and support needs of men with lupus. Toral and colleagues at HSS set out to identify their self-reported needs and concerns, as well as their potential interest in support forums geared toward men.

An 85-question survey was disseminated nationally to males over 18 with lupus. The survey was advertised via online forums, at major hospitals serving lupus patients in New York City and through local and national lupus groups. The survey assessed four core areas: health status and quality of life, health behavior and lifestyle, access to care and interest in programs specifically designed for men. Participants completed the surveys via an online link.

A total of 112 respondents participated in the survey, with 61% identified as white, 21% as black/African-American, 15% as Hispanic and 31% as other. Mean age was 26 and mean time since diagnosis was 10 years. Forty-nine percent of males were employed/self-employed, while 46% were unemployed/unable to work. Fifty-three percent had an annual income of more than $50,000 and 59% had some college or an advanced degree. Ninety-four percent reported having health insurance. Almost all (92%) were being treated by a rheumatologist.

The researchers reported the following findings:

"This study provides important information about the physical and emotional health of males with lupus, as well as their interest in psychosocial support," said Toral. "The next step would be to conduct focus groups to better understand their specific support needs, with the ultimate goal of developing programs to ensure those needs are being met."

Additional study authors include Jillian Rose, PhD, MPH, LCSW; Roberta Horton, LCSW, ACSW; Ambar Tavera; and Natalia Irvine, MPH, all from HSS.

About HSS

HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report "Best Children's Hospitals" list (2019-2020). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In addition, HSS will be opening a new facility in Florida in early 2020. In 2018, HSS provided care to 139,000 patients and performed more than 32,000 surgical procedures, and people from all 50 U.S. states and 80 countries travelled to receive care at HSS. There were more than 37,000 pediatric visits to the HSS Lerner Children's Pavilion for treatment by a team of interdisciplinary experts. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is the world's leading provider of education on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

SOURCE Hospital for Special Surgery


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: